These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17979768)

  • 1. The SeeDs approach: integrating fragments into drug discovery.
    Hubbard RE; Davis B; Chen I; Drysdale MJ
    Curr Top Med Chem; 2007; 7(16):1568-81. PubMed ID: 17979768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using computational techniques in fragment-based drug discovery.
    Desjarlais RL
    Methods Enzymol; 2011; 493():137-55. PubMed ID: 21371590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits of constructing leads from fragment hits.
    Foloppe N
    Future Med Chem; 2011 Jul; 3(9):1111-5. PubMed ID: 21806375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.
    Albert JS; Blomberg N; Breeze AL; Brown AJ; Burrows JN; Edwards PD; Folmer RH; Geschwindner S; Griffen EJ; Kenny PW; Nowak T; Olsson LL; Sanganee H; Shapiro AB
    Curr Top Med Chem; 2007; 7(16):1600-29. PubMed ID: 17979771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions.
    Hesterkamp T; Barker J; Davenport A; Whittaker M
    Curr Top Med Chem; 2007; 7(16):1582-91. PubMed ID: 17979769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based drug design: computational & experimental state of the art.
    Hoffer L; Renaud JP; Horvath D
    Comb Chem High Throughput Screen; 2011 Jul; 14(6):500-20. PubMed ID: 21521152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment screening for drug leads by weak affinity chromatography (WAC-MS).
    Ohlson S; Duong-Thi MD
    Methods; 2018 Aug; 146():26-38. PubMed ID: 29378316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based drug discovery: what has it achieved so far?
    Alex AA; Flocco MM
    Curr Top Med Chem; 2007; 7(16):1544-67. PubMed ID: 17979767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences in fragment-based lead discovery.
    Hubbard RE; Murray JB
    Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
    Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
    J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical aspects of NMR-based fragment discovery.
    Zartler ER; Mo H
    Curr Top Med Chem; 2007; 7(16):1592-9. PubMed ID: 17979770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.